GWPH - GW Pharmaceuticals Plc Remains A Solid Growth Story
- GW Pharmaceuticals' latest earnings report reinforces the narrative that the company's future growth trajectory looks solid.
- Epidiolex still has a lot of growth potential in the short and long term, with a lot of market share remaining to be taken in different segments.
- For now there are no concerns over being too reliant upon Epidiolex because of the decentralized nature of the conditions being treated.
- The company has several different programs that are in different phases that, if successful, will provide more growth catalysts over time.
For further details see:
GW Pharmaceuticals Plc Remains A Solid Growth Story